En EspañolBy Amy Norton HealthDay ReporterWEDNESDAY, June 12, 2019 (HealthDay News) -- Monitoring a melanoma patient's progress is challenging. But a laser-based test might allow doctors to quickly screen the patient's blood to spot tumor cells roaming the body, a preliminary study suggests.
Those cells, known as circulating tumor cells, are "shed" from the original cancer site into the blood vessels or lymph system. They are considered a potential red flag. They could be a sign that a current treatment is not working, or that the cancer is more likely to spread to distant sites in the body.
"For some patients in our study, ctDNA (circulating tumor DNA) levels measured in a relatively simple blood test revealed tumor mutations that could be potentially targeted with current or new drugs that inhibit tumor growth mutations that are not revealed by genetic profiling of the tumor itself," says Evan Lipson, M.D., an associate professor of oncology at the Kimmel Cancer Center and a member of The Bloomberg~Kimmel Institute for Cancer Immunotherapy.
Right now, though, doctors have no good way to detect circulating tumor cells. They are not abundant, so they can easily be missed by analyzing a patient's blood sample.
Related ArticlesAnd it's simply not feasible to draw large amounts of blood from a patient, explained Vladimir Zharov, the senior researcher on the new study.He is chair of cancer research at the University of Arkansas for Medical Sciences, in Little Rock.Zharov's team has been developing an alternative to blood draws. It's a laser-based system designed to screen patients' blood from the outside -- spotting tumor cells as they pass through veins in the arm.
Pharmacogenomics/genome sequencing. Personalized medicine continues to edge closer to the forefront of the healthcare industry. Tailoring treatment plans to individuals and anticipating the onset of certain diseases offers promising benefits for healthcare efficiency and diagnostic accuracy. Pharmacogenomics in particular could help reduce the billions of dollars in excess healthcare spending due to adverse drug events, misdiagnoses, readmissions and other unnecessary costs.
In a nutshell, Zharov explained, it works like this: Laser pulses are applied to a vein through the skin. If melanoma cells -- which contain the light-absorbing pigment melanin -- cross the laser beam, they produce a sound wave. That, in turn, is captured by a small ultrasound probe placed on the skin.Melanoma is the least common but deadliest form of skin cancer.
In this study, the researchers found that the system detected circulating tumor cells in 27 of 28 patients with later-stage melanoma -- in as little as 10 seconds. And it generated no false alarms when used to screen 19 healthy volunteers.
According to Zharov, the approach was 1,000 times more sensitive than previous tests researchers have developed for catching circulating tumor cells.
The findings are an early step. Melanoma experts said much more research is needed."This is a fascinating study," said Dr. Zeynep Eroglu, a skin cancer specialist at Moffitt Cancer Center, in Tampa, Fla.There is a need for blood-based tests in monitoring patients with more advanced melanoma, she said. Doctors can use CT scans to see whether a treatment is working, but those scans can only be done every three months or so, Eroglu explained.
Medical technology innovations: Electronic Aspirin. For people who suffer from migraines, cluster headaches, and other causes of chronic, excruciating head or facial pain, the "take two aspirins and call me in the morning" method is useless. Doctors have long associated the most severe, chronic forms of headache with the sphenopalatine ganglion (SPG), a facial nerve bundle, but haven't yet found a treatment that works on the SPG long-term. A technology under clinical investigation at Autonomic Technologies, Inc., (Redwood City, CA) is a patient-powered tool for blocking SPG signals at the first sign of a headache. The system involves the permanent implant of a small nerve stimulating device in the upper gum on the side of the head normally affected by headache. The lead tip of the implant connects with the SPG bundle, and when a patient senses the onset of a headache, he or she places a handheld remote controller on the cheek nearest the implant. The resulting signals stimulate the SPG nerves and block the pain-causing neurotransmitters.
A blood test could be done more often.
"The inherent limitation is the amount of blood you need to draw," Eroglu said. "This system essentially gets around that."
However, it's not yet clear what doctors can do with the finding that a patient has some circulating tumor cells.
Eroglu said future studies could, for instance, follow melanoma patients after they receive treatment. "You could look at how well the detection of circulating tumor cells correlates with patients' outcomes," she said.
Other researchers have been working on blood tests that detect bits of DNA from tumor cells, Eroglu noted. There is evidence that among patients who've had surgery for earlier-stage melanoma, those with detectable tumor DNA afterward have a higher risk of relapse, she said.
One of the researchers working on those tests is Dr. David Polsky, a professor of dermatologic oncology at NYU Langone Health, in New York City. He agreed that the current study is "interesting.""But a lot more validation work needs to be done before it could be used clinically," Polsky said.
According to Zharov, the approach holds promise for not only monitoring melanoma patients' responses to treatment, but also catching any recurrences after treatment, or helping to diagnose the cancer in the first place.
Gamifying behavior change. Adherence and compliance represent crucial issues in improving patients’ health and decreasing the cost of delivering healthcare. Several start-ups have targeted this issue with different solutions such as a pill bottle that glows blue when a medication dose should be taken and red when a dose is missed (winner of the Healthcare Innovation World Cup); or tiny digestible sensors that can be placed in pills and can transmit pill digestion data to physicians and family members. While patients do not like the term adherence as they want to be partners with their caregivers rather than following orders, health insurance companies will use more and more data to check whether the patients comply with their prescriptions to decrease their insurance costs. The wildly popular Pokemon Go motivates people to walk more which might lead to fighting obesity while playing a game.
There are also hints that the laser might even kill off some of the circulating tumor cells.
For now, though, Zharov said his team is focused on using the technology for diagnosis and monitoring.
There's also the question of whether the test could weed out circulating tumor cells from other types of cancer. Zharov said that is possible -- though the approach would have to be modified because other types of tumor cells do not contain melanin.The American Cancer Society estimates that about 96,500 Americans will be diagnosed with melanoma this year, and over 7,200 will die from the disease.
When melanoma is caught early, it is highly curable. Once it has spread to distant sites, like the lungs or brain, the five-year survival rate is about 23%, the cancer society says.The study was published June 12 in Science Translational Medicine.
The American Cancer Society has more on melanoma.